Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.

Anilides / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Renal Cell / drug therapy Humans Kidney Neoplasms / drug therapy Nivolumab / therapeutic use Pyridines / therapeutic use Treatment Outcome
Advanced modeling Individualized cancer therapy Treatment algorithm

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 05 07 2018
revised: 18 10 2018
accepted: 18 10 2018
pubmed: 8 11 2018
medline: 10 9 2019
entrez: 8 11 2018
Statut: ppublish

Résumé

Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved. Two independent reviewers performed study selection, data extraction, and risk of bias assessment. Indirect treatment comparisons were carried out by directly assessing HR differences and statistical modeling of Kaplan-Meier curves from these two trials. Publications identified showed that no head-to-head comparisons had been carried out. Two indirect treatment comparisons used agreed that there was no significant difference in OS between cabozantinib and nivolumab and that cabozantinib significantly improved PFS compared to nivolumab. The field of aRCC treatments is evolving rapidly, creating opportunities for individualized treatments and challenges for clinicians to keep up with the evidence. In lieu of availability of direct comparisons of all options, advanced modeling results presented herein can help to inform and improve personalized treatments.

Sections du résumé

BACKGROUND BACKGROUND
Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved.
METHODS METHODS
Two independent reviewers performed study selection, data extraction, and risk of bias assessment. Indirect treatment comparisons were carried out by directly assessing HR differences and statistical modeling of Kaplan-Meier curves from these two trials.
RESULTS RESULTS
Publications identified showed that no head-to-head comparisons had been carried out. Two indirect treatment comparisons used agreed that there was no significant difference in OS between cabozantinib and nivolumab and that cabozantinib significantly improved PFS compared to nivolumab.
CONCLUSIONS CONCLUSIONS
The field of aRCC treatments is evolving rapidly, creating opportunities for individualized treatments and challenges for clinicians to keep up with the evidence. In lieu of availability of direct comparisons of all options, advanced modeling results presented herein can help to inform and improve personalized treatments.

Identifiants

DOI: 10.1016/j.critrevonc.2018.10.004 PMID: 30401604
pubmed: 30401604
pii: S1040-8428(18)30321-4
doi: 10.1016/j.critrevonc.2018.10.004
pii:
doi:

Substances chimiques

Anilides 0
Antineoplastic Agents, Immunological 0
Pyridines 0
cabozantinib 1C39JW444G
Nivolumab 31YO63LBSN

Types de publication

Comparative Study Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-148

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Camillo Porta (C)

Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, via S. Maugeri 10, 27100 Pavia, Italy. Electronic address: camillo.porta@unipv.it.

Cezary Szczylik (C)

Warsaw Medical University, Żwirki i Wigury 61, 02-091 Warsaw, Poland. Electronic address: cszczylik@wp.pl.

Roman Casciano (R)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: R.Casciano@analytica-laser.com.

Shuai Fu (S)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: S.Fu@analytica-laser.com.

Billy Amzal (B)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: B.Amzal@analytica-laser.com.

Johanna Lister (J)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: J.Lister@analytica-laser.com.

Helene Karcher (H)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: H.Karcher@analytica-laser.com.

Jie Meng (J)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: J.Meng@analytica-laser.com.

Monika Neumann (M)

Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: M.Neumann@analytica-laser.com.

Jerome Dinet (J)

Ipsen Pharma SAS, 65 quai Georges Gorse, Boulogne-Billancourt, Ile-de-France, France. Electronic address: postmaster@jeromedinet.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Amines › Dérivés de l'aniline › Anilides › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Nivolumab › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Second-line cabozantinib versus nivolumab in...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Second-line cabozantinib versus nivolumab in...